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Twenty-six percent (50/175) of these patients had more than 2 tumors. 
Greatest tumor size, female sex, T-, N-, M- and overall stage were all 
signiﬁcant predictors of survival (p <0.05). Compared with patients 
with similar histologies (n=146) those with different histologies (n=29) 
had greater 3-year survival (72 months [95%CI: 62-80] versus 47 
months [95%CI: 25-67], respectively). Neither tumor location (ipsi-
lateral vs. contralateral), the time of SPLC diagnosis (preoperatively 
versus intra- or postoperatively), or smoking history had an impact 
on survival. Median overall survival was 74 months (95%CI: 60-not 
estimable), with a 3-year overall survival of 67 % (95%CI: 58-75). 
Evaluating by the highest pathological stage lesion, patients with 
SPLC tumors had comparable 3-year survival rates to those expected 
in patients with similar stage single primary cancers (Graph). Twenty-
seven patients who had same lobe disease had a 3-year survival of 77% 
(95%CI: 53-90).
Conclusions: Identiﬁcation of SPLC by clinical and pathologic criteria 
coupled with aggressive treatment can lead to results that approach 
those seen with similar stage single primary disease. In particular, pa-
tients with synchronous disease in the same lobe, who otherwise would 
have been considered T4, have better than predicted survival.
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Background: The phase III EORTC trial 22993-08993 demon-
strated that PCI signiﬁcantly reduces the risk of brain metastases 
(BM) (40.4% vs 14.6% at 1 yr) and prolongs survival (27.1% vs 
13.3% at 1 yr) in patients with ED- SCLC (ASCO 2007). Preventing 
BM will without any doubt prevent deterioration of QoL. However, the 
effects of PCI in cases who did not develop BM are uncertain. We now 
report the QoL results in that study.
Methods: Patients (18-75 years; ≤WHO2) with conﬁrmed ED-SCLC 
and showing response to induction chemotherapy, were randomized 
to PCI (doses ranging from 20 Gy/5 fr to 30 Gy/12 fr) or no PCI. QoL 
data (QLQ-C30 and BN20) were collected at baseline (i.e. at randomi-
sation within 5 weeks after last chemotherapy), 6 weeks, 3, 6, 9 and 12 
months and then every six months until 3 years or death. The primary 
QoL endpoints were global health status, hair loss, fatigue, role, cogni-
tive and emotional functioning. QoL scales range from 0-100: for 
function higher values represent better function, for symptoms higher 
values indicate greater symptom burden. Clinical signiﬁcance is a 10-
point difference, statistical signiﬁcance is P<0.01
Results: Between October 2001-March 2006, 286 patients entered the 
trial. Baseline characteristics were well balanced. Compliance to QoL 
was 93.7% (268/286) at baseline, 60.0% (162/270) at 6 weeks, 54.4% 
(128/235) at 3, 60.8% (79/130) at 6, and 46.3% (38/82) at 9 months 
and was not signiﬁcantly different between the two groups. The median 
survival (measured from time of randomization) was 6 months. The 
data from baseline to month 9 showed no statistically or clinically 
signiﬁcant difference in global health status (p=0.10). Main side effects 
of PCI were signiﬁcant hair loss and fatigue (see table), but no impact 
on role (p=0.17), cognitive (p=0.07) or emotional functioning (p=0.18) 
was observed. Exploratory analyses of the QoL scales showed statisti-
cally signiﬁcant and (near) clinically relevant differences for appetite 
loss, nausea/vomiting and weakness of legs in the ﬁrst months after 
PCI (see table). 
HE QoL score
Assessment 
time
PCI  
Score (SD)
Control 
Score (SD)
Treatment 
diﬀerence 
p-value
Hair loss 6 weeks 36.5 (3.96) 11.7 (3.73) <0.001
Fatigue 6 weeks 43.2 (2.56) 29.3 (2.47) <0.001
Fatigue 3 months 53.6 (3.03) 38.5 (3.24) <0.001
Appetite loss 6 weeks 28.9 (3.25) 10.6 (3.06) <0.001
Appetite loss 3 months 43.9 (3.87) 14.8 (4.18) <0.001
Nausea/vomiting 6 weeks 15.0 (1.73) 5.3 (1.64) <0.001
Nausea/vomiting 3 months 26.9 (2.92) 8.2 (3.15) <0.001
Weakness of legs 6 weeks 25.2 (2.71) 11.8 (2.48) <0.001
Weakness of legs 3 months 32.2 (3.62) 16.0 (3.93) 0.0026
 
Conclusions: Despite signiﬁcant early side effects of PCI, global health 
status was not signiﬁcantly inﬂuenced till far beyond the expected 
median survival of these patients. Patients with ED SCLC who respond 
to chemotherapy should routinely be offered PCI. 
This study was performed by the EORTC Radiation Oncology and 
Lung Cancer Groups.
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